These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28682462)

  • 1. Need to Recalibrate Research Outcomes in Alzheimer's Disease: Focus on Neuropsychiatric Symptoms.
    Canevelli M; Cesari M; Lucchini F; Valletta M; Sabino M; Lacorte E; Vanacore N; Bruno G
    J Am Geriatr Soc; 2017 Sep; 65(9):2071-2073. PubMed ID: 28682462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Nakajima S; Plitman E; Mihashi Y; Hayashi S; Mimura M; Nakayama K
    J Alzheimers Dis; 2016; 50(3):839-45. PubMed ID: 26836181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroimaging correlates of neuropsychiatric symptoms in Alzheimer's disease: a review of 20 years of research.
    Boublay N; Schott AM; Krolak-Salmon P
    Eur J Neurol; 2016 Oct; 23(10):1500-9. PubMed ID: 27435186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): study protocol for a randomized controlled trial.
    Forstmeier S; Maercker A; Savaskan E; Roth T
    Trials; 2015 Nov; 16():526. PubMed ID: 26576633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns.
    Chen Y; Dang M; Zhang Z
    Mol Neurodegener; 2021 Jun; 16(1):38. PubMed ID: 34099005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.
    Daviglus ML; Bell CC; Berrettini W; Bowen PE; Connolly ES; Cox NJ; Dunbar-Jacob JM; Granieri EC; Hunt G; McGarry K; Patel D; Potosky AL; Sanders-Bush E; Silberberg D; Trevisan M
    NIH Consens State Sci Statements; 2010 Apr; 27(4):1-30. PubMed ID: 20445638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race reporting and disparities in clinical trials on Alzheimer's disease: A systematic review.
    Canevelli M; Bruno G; Grande G; Quarata F; Raganato R; Remiddi F; Valletta M; Zaccaria V; Vanacore N; Cesari M
    Neurosci Biobehav Rev; 2019 Jun; 101():122-128. PubMed ID: 30946856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis.
    Wang J; Yu JT; Wang HF; Meng XF; Wang C; Tan CC; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):101-9. PubMed ID: 24876182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.
    Lanctôt KL; Amatniek J; Ancoli-Israel S; Arnold SE; Ballard C; Cohen-Mansfield J; Ismail Z; Lyketsos C; Miller DS; Musiek E; Osorio RS; Rosenberg PB; Satlin A; Steffens D; Tariot P; Bain LJ; Carrillo MC; Hendrix JA; Jurgens H; Boot B
    Alzheimers Dement (N Y); 2017 Sep; 3(3):440-449. PubMed ID: 29067350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Older patients are still under-represented in clinical trials of Alzheimer's disease.
    Banzi R; Camaioni P; Tettamanti M; Bertele' V; Lucca U
    Alzheimers Res Ther; 2016 Aug; 8():32. PubMed ID: 27520290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychiatric symptoms in Alzheimer's disease and vascular dementia.
    Echávarri C; Burgmans S; Uylings H; Cuesta MJ; Peralta V; Kamphorst W; Rozemuller AJ; Verhey FR
    J Alzheimers Dis; 2013; 33(3):715-21. PubMed ID: 23001706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcranial direct current stimulation for depression in Alzheimer's disease: study protocol for a randomized controlled trial.
    Narita Z; Yokoi Y
    Trials; 2017 Jun; 18(1):285. PubMed ID: 28629447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex and gender differences in the treatment of Alzheimer's disease: A systematic review of randomized controlled trials.
    Canevelli M; Quarata F; Remiddi F; Lucchini F; Lacorte E; Vanacore N; Bruno G; Cesari M
    Pharmacol Res; 2017 Jan; 115():218-223. PubMed ID: 27913252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review.
    Terum TM; Andersen JR; Rongve A; Aarsland D; Svendsboe EJ; Testad I
    Int J Geriatr Psychiatry; 2017 Jul; 32(7):703-717. PubMed ID: 28317166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.